Browse > Article

Docetaxel and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Cancer  

Cho Eun-Hee (Department of Internal Medicine, Seoul Veterans Hospital)
Cho Keun-Hyok (Department of Internal Medicine, Seoul Veterans Hospital)
Song Young-Bong (Department of Internal Medicine, Seoul Veterans Hospital)
Choi Ik-Sung (Department of Internal Medicine, Seoul Veterans Hospital)
Choi Jae-Won (Department of Internal Medicine, Seoul Veterans Hospital)
Nam Seung-Hyun (Department of Internal Medicine, Seoul Veterans Hospital)
Kim Bong-Seog (Department of Internal Medicine, Seoul Veterans Hospital)
Publication Information
Korean Journal of Head & Neck Oncology / v.21, no.2, 2005 , pp. 126-131 More about this Journal
Abstract
Objectives: To evaluate the efficacy and safety of induction chemotherapy with docetaxel and cisplatin in locally advanced head and neck cancer. Materials and Methods: Between June 1998 and December 2004, 30 patients were enrolled and among them, 20 patients were evaluable. Patients were treated with docetaxel $75mg/m^2$ and cisplatin $60mg/m^2$ on day 1 every 21 days. Results: The median age was 71(range 54-80) years old. All 20 patients were male. Nineteen patients had pathologically squamous cell carcinoma and 1 had undifferentiated carcinoma. Fourteen of 20 patients(70%) demonstrated an objective response with two(10%) achieving a complete clinical response and eleven(60%) a partial response. The median response duration was 5.3(1.6-32.1) months and the median time to progression was 5.6(1.4-33.8) months. The median overall survival of all patients was 14(range 2.2-34) months. The median overall survival of responders was 17.5(range 5-34) months and that of non-responders was 3.2(range 2.2-23) months, but it was not statistically significant(p=0.106). During a total of 92 cycles, granulocytopenia worse than CTC(Common toxicity criteria) grade 2 occurred in 6%, thrombocytopenia in 2%, and anemia in 3%, respectively. Non-hematologic toxicities were minor and easily controlled. Conclusion: The induction chemotherapy of docetaxel and cisplatin has moderate efficacy with acceptable toxicities in patients with locally advanced head and neck cancer.
Keywords
Head and neck cancer; Docetaxel; Cisplatin;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ervin TJ, Clark JR, Weichselbaum RR: Multidisciplinary treatment of advanced squamous carcinoma of the head and neck. Semin Oncol. 1985;12 (4 Suppl 6):71-78
2 Wittes R, Heller K, Randolph V, et al: Cis-diamminedichloroplatinum(II)-based chemotherapy as initial treatment of advanced head and neck cancer. Cancer Treat Rep. 1979;63:1533-1538
3 Kim HK, Han JY, Kang JH, et al: Induction chemotherapy using 5-FU and cisplatin and radiotherapy in patients with locally advanced head and neck cancer. Korean J Medicine. 1995:49: 484-491
4 Weaver A, Flemming S, Kish J, et al: Cis-platinum and 5-Fluorouracil as induction therapy for advanced head and neck cancer. Am J Surg. 1982;144:445-448   DOI   ScienceOn
5 Park JH, Choi HS, Kim JH, et al: Neoadjuvant chemotherapy with 5-fluorouracil and cisplatin for locally advanced head and neck cancer. J Korean Cancer Assoc. 1995;27:990-1001
6 Forastiere A, Glisson B, Murphy B, O'Connell B: A Phase II study of docetaxel and cisplatin in patients with locally advanced, recurrent, and/or metastatic squamous cell carcinoma of the head and neck (SCCHN), not curable by standard therapy. Proc Am Soc Clin Oncol. 1998; 17: 399a
7 Lamont EB, Vokes EE: Chemotherapy in the management of squamous-cell carcinoma of the head and neck. Lancet Oncol. 2001 ;2:261-269   DOI   ScienceOn
8 Forastiere A, Koch W, Trotti A, Sidransky D: Head and neck cancer. N Engl J Med. 2001;345:1890-1900   DOI   ScienceOn
9 Vokes EE, Weichelbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Eng J Med. 1993;21:184-194
10 Lee JH, Lee KW, Choi YJ, et al. Docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinomas of the head and neck. Cancer Research and Treatment. 2003;35:261-266   DOI
11 Laramore GE, Scott CB, Al-sarraf M, et al: Adjuvant chemotherapy for respectable squamous cell carcinomas of the head and neck: report on intergroup study 0034. Int J Radiation Oncology Biol Physi. 1992;23:705-713   DOI   ScienceOn
12 Schofski P, Catimel G, Planting AST, et al: Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol. 1999; 10: 119-122   DOI   ScienceOn
13 The department of veterans affairs laryngeal cancer study group: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324 (24):1685-1690   DOI   ScienceOn
14 Amer MH, Al-sarraf M, Vaitkevicius VK: Factors that affect response to chemotherapy and survival of patients with advanced head and neck cancer. Cancer. 1979;43:2202-2206   DOI   PUBMED   ScienceOn
15 Catimel G, Verweij J, Mattijssen V, et al: Docetaxel (Taxotere): An active drug for treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol. 1994;5:533-537   DOI
16 Jacobs C, Goffinet DR, Goffinet L, Kohler M, Fee WE: Chemotherapy as a substitute for surgery in the treatment of advanced resectable head and neck cancer. A report from the northern california oncology group. Cancer. 1987;60 (6) :1178-1183   DOI   PUBMED   ScienceOn
17 Lee GT, Byun JH, Hwangbo K, et all: Comparision of radiation therapy and combined chemotherapy and radiation therapy for locally advanced head and neck cancer. J Korean Cancer Assoc. 1997;29:616-622